Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1829-1835

  Rom, Joachim ^a   von Minckwitz, G ^b   Marme F ^a   Ataseven, B ^c   Kozian, D ^d   Sievert, M ^d   Schlehe, B ^a   Schuetz, F ^a   Scharf, A ^a   Kaufmann, M ^b   Sohn, C ^a   Schneeweiss, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Red Cross Hospital   (Germany)

^d Sanofi Aventis Dt GmbH   (Germany)

Author keywords

Apoptosis; Breast cancer; Oblimersen

Indexed keywords

BETA 2 MICROGLOBULIN; BIRC2 PROTEIN; BIRC3 PROTEIN; CYCLOPHILIN A; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; INHIBITOR OF APOPTOSIS PROTEIN; OBLIMERSEN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN PROCESSING; TUMOR BIOPSY;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOWN-REGULATION; DOXORUBICIN; FEMALE; GENE EXPRESSION; GENES, BCL-2; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PREOPERATIVE PERIOD; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAXOIDS; THIONUCLEOTIDES;

EID: 71049185934     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp208     Document Type: Article

References (32)

1. Kaufmann M, Hortobagyi GN, Goldhirsch A et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 2006; 24: 1940-1949.
2. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999; 11: 68-75.
3. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-157.
4. Reed JC. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995; 9: 451-473.
5. Berardo MD, Elledge RM, de Moor C et al. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 1998; 82: 1296-1302.
6. Webb A, Cunningham D, Cotter F et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137-1141.
7. van de Donk NW, Kamphuis MM, van Dijk M et al. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003; 17: 211-219.
8. Shangary S, Johnson DE. Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 2003; 17: 1470-1481.
9. Chi KN, Murrary RN, Gleave ME et al. A phase II study of oblimersen sodium (G3139) and docetaxel (D) in patients (pts) with metastatic hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2003: 22 (Abstr 393).
10. Klasa RJ, Bally MB, Ng R et al. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 2000; 6: 2492-2500.
11. Klasa RJ, List AF, Cheson BD. Rational approaches to design of therapeutics targeting molecular markers. Hematology Am Soc Hematol Educ Program 2001; 2001: 443-462.
12. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 2000; 6: 2891-2902.
13. Vrignaud P, Lejeune P, Klem R, Bissery M-C. Combination of G3139 genasenseTM, a bcl-2 antisense oligonukleotide, with docetaxel (taxotere (R)) is active in a murine xenograft model of human non-small cell lung cancer. Proc Am Assoc Cancer Res 2002; 43: 578.
14. Rom J, von Minckwitz G, Eiermann W et al. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: Final results of a multicentric phase I study. Ann Oncol 2008; 19: 1698-1705.
15. Rodriguez C, Hughes-Davies L, Valles H et al. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res 2004; 10: 5785-5791.
16. ten Asbroek AL, van Groenigen M, Nooij M, Baas F. The involvement of human ribonucleases H1 and H2 in the variation of response of cells to antisense phosphorothioate oligonucleotides. Eur J Biochem 2002; 269: 583-592.
17. Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994; 5 (Suppl 1): 61-65.
18. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000; 6: 1029-1035.
19. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17: 2941-2953.
20. Hersey P, Zhang XD. Overcoming resistance of cancer cells to apoptosis. J Cell Physiol 2003; 196: 9-18.
21. Jansen B, Schlagbauer-Wadl H, Brown BD et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 4: 232-234.
22. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902-3907.
23. Yang D, Ling Y, Almazan M et al. Tumor regression of human breast carcinomas by combination therapy of anti-bcl-2 antisense oligonucleotide and chemotherapeutic drugs. Proc Am Assoc Cancer Res 1999; 40: 729.
24. Tolcher A, Miyake H, Gleave ME. Down-regulation of Bcl-2 expression by antisense oligonucleotide (AS-ODN) treatment enhances mitoxantrone cytotoxicity in the androgen-dependent Shionogi tumor model. Proc Am Assoc Cancer Res 1999; 40: 3198.
25. Miyake H, Tolcher A, Gleave ME. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res 1999; 59: 4030-4034.
26. Leonard JP, Coleman M, Vose J et al. Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma (MCL). Proc Am Soc Clin Oncol 2003; 22: 631.
27. Morris MJ, Tong WP, Cordon-Cardo C et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8: 679-683.
28. de Bono JS, Rowinsky EK, Kuhn J et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of bcl-2 antisense (Genasense) and docetaxel (D) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2001; 20: 81.
29. Jansen BWV, Heere-Ress E, Hoeller C et al. Clinical, pharmacologic, and pharmacodynamic study of genasense (G3139, Bcl-2 antisense oligonucleotide) and dacarbazine (DTIC) in patients with malignant melanoma. Proc Am Soc Clin Oncol 2001; 20: (Abstr 1426).
30. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-760.
31. Zhao Q, Song X, Waldschmidt T et al. Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation. Blood 1996; 88: 1788-1795.
32. Chang JC, Wooten EC, Tsimelzon A et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369.